Delivery Order 36C24E20D0028-36C24E21N0179
- Not listed
- The U.S. federal government awarded a delivery order valued at $9.87 million to Infinity Biologix LLC for genomic analysis services. The contract, awarded on September 30, 2020, with a completion date of May 2, 2024, represents a firm fixed-price engagement with no socioeconomic set-aside designation. The work will be performed in Washington, DC, and the funding originates from a civilian federal agency. Infinity Biologix LLC, operating through its Sampled Division and based in Piscataway, New...
- The U.S. government awarded a $6.3 million firm fixed-price delivery order for genomic analysis services to Infinity Biologix LLC (doing business as Sampled Division), a biomedical research company based in Piscataway, New Jersey. The contract, awarded on September 30, 2023, with an ultimate completion date of September 29, 2025, will be performed in Washington, DC and funded by a civilian federal agency. This delivery order represents no set-aside designation and is part of the company's...
- The U.S. Department of Veterans Affairs awarded a $4.4 million firm fixed-price delivery order to Infinity Biologix LLC for genomic analysis services, effective September 30, 2024, with completion targeted for September 29, 2025. Infinity Biologix, based in Piscataway, New Jersey, and operating through its Sampled Division, is a specialized biomedical research firm providing comprehensive genomic sequencing, DNA extraction, genotyping, and biorepository solutions to multiple federal agencies....
- The U.S. Department of Veterans Affairs has awarded a $6.3 million firm fixed-price delivery order to Infinity Biologix LLC for genomic analysis services. The award, issued on September 30, 2025, with an ultimate completion date of March 29, 2026, does not include a socioeconomic set-aside. Work will be performed in Washington, DC. Infinity Biologix LLC, a for-profit limited liability company based in Piscataway, New Jersey, operating through its Sampled Division, specializes in advanced...
- This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health National Institute on Aging to Infinity Biologix LLC, a biorepository and laboratory services company, for DNA extraction and genotyping services. The contract is a firm fixed-price purchase order valued at $182,183.00, with a completion date of September 21, 2022. The contract does not have a set-aside designation. Infinity Biologix, through its Sampled division, has provided...
- This is a delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Infinity Biologix LLC, doing business as Sampled Division. The $2,712,502.66 firm-fixed-price contract is for the NIDA Center for Genetic Studies, covering the period from March 14, 2025 to March 13, 2026. The contract does not have a set-aside designation. Infinity Biologix is a leading provider of genomic analysis, sequencing, DNA extraction, genotyping, and biorepository services to...
- The Department of Veterans Affairs, Veterans Integrated Service Network 1 (VISN 1), awarded a delivery order to Infinity Biologix LLC for long read sequencing services with a ceiling value of $1.19M. The contract employs firm fixed-price pricing with an ultimate completion date of March 1, 2027, and work will be performed in Piscataway, New Jersey. This delivery order was issued without a set-aside designation and represents task ordering under an existing vehicle established with the VA....
- The National Institute on Drug Abuse (NIDA) awarded a delivery order valued at $2.96 million to Infinity Biologix LLC for continued operation of the NIDA Center for Genetic Studies. This task order (75N95026F00001, designated TO4) runs from March 14, 2026 through March 13, 2027 and represents work performed at the contractor's facility in Piscataway, New Jersey. The award utilizes a firm-fixed-price contract structure with no socioeconomic set-aside and is part of a larger $15 million indefinite...
- This federal contract award is for DNA extraction and genotyping services in support of the iPSC Neurodegeneration Initiative project at the National Institute on Aging (NIA), which is part of the Department of Health and Human Services (HHS) National Institutes of Health (NIH). The $146,111 firm-fixed-price purchase order was awarded to Infinity Biologix LLC, a biorepository and laboratory services company, to perform automated DNA extraction and array-based genotyping on 1,256 cell line...
- This is a firm fixed-price delivery order contract awarded by the National Institute on Aging, a Civilian agency, to Illumina, Inc., a manufacturer of genetic sequencing and array-based analysis equipment and reagents. The contract, valued at $69,572.16, is for the delivery of Illumina's Infinium Global Diversity Array-8+ V1.0 Kits, which are laboratory supplies used for genetic analysis. This award is not associated with a set-aside program. Illumina has previously received prime federal...
- 36C24E20D0028Indefinite Delivery Contract
- 36C24E20D0028-36C24E21N0179Delivery Order
Infinity Biologix LLC, operating as the Sampled Division and based in Piscataway, New Jersey, was awarded a delivery order valued at $13.5 million for genomic analysis services. The contract, issued on September 30, 2021, with an ultimate completion date of September 29, 2022, carries firm fixed-price terms and was funded by a civilian federal agency headquartered in Washington, DC. No socioeconomic set-aside was applied to this award. The delivery order represents a continuation of Infinity Biologix's established role as a specialized provider of advanced biomedical and genomic research services to multiple federal agencies. Infinity Biologix has demonstrated substantial capacity and expertise in high-complexity laboratory work, including next-generation sequencing, DNA extraction, genotyping, and biorepository solutions. The company's federal contract portfolio reflects extensive experience supporting agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, National Institute on Drug Abuse, and Department of Veterans Affairs. The contractor also holds significant indefinite delivery contracts, including a $149.2 million IDV with the National Cancer Institute for genome characterization services and a $15 million contract with the National Institute on Drug Abuse for genetic studies support, positioning the company as a strategically important provider of genomic research infrastructure and capabilities for federal scientific initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.5m | 9/23/21 |